[PDF][PDF] Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor

…, Y Xiao, L Jin, KW Kuntz, R Chesworth, MP Moyer… - Cancer cell, 2011 - cell.com
Mislocated enzymatic activity of DOT1L has been proposed as a driver of leukemogenesis
in mixed lineage leukemia (MLL). The characterization of EPZ004777, a potent, selective …

A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells

…, JJ Smith, EJ Olhava, R Chesworth, MP Moyer… - Nature chemical …, 2012 - nature.com
EZH2 catalyzes trimethylation of histone H3 lysine 27 (H3K27). Point mutations of EZH2 at
Tyr641 and Ala677 occur in subpopulations of non-Hodgkin's lymphoma, where they drive …

Target genes of β-catenin–T cell-factor/lymphoid-enhancer-factor signaling in human colorectal carcinomas

…, M Ilyas, WF Bodmer, MP Moyer… - Proceedings of the …, 1999 - National Acad Sciences
Mutations in the adenomatous polyposis coli or β-catenin gene lead to cytosolic accumulation
of β-catenin and, subsequently, to increased transcriptional activity of the β-catenin–T cell-…

Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase

…, A Cunningham, C DiOrio, J Doty, MJ Morin, MP Moyer… - Cancer research, 1997 - AACR
The epidermal growth factor receptor (EGFR) is overexpressed in a significant percentage
of carcinomas and contributes to the malignant phenotype. CP-358,774 is a directly acting …

Potent inhibition of DOT1L as treatment of MLL-fusion leukemia

…, NJ Waters, R Chesworth, MP Moyer… - Blood, The Journal …, 2013 - ashpublications.org
Rearrangements of the MLL gene define a genetically distinct subset of acute leukemias
with poor prognosis. Current treatment options are of limited effectiveness; thus, there is a …

Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2

…, R Chesworth, MP Moyer… - Proceedings of the …, 2013 - National Acad Sciences
Inactivation of the switch/sucrose nonfermentable complex component SMARCB1 is extremely
prevalent in pediatric malignant rhabdoid tumors (MRTs) or atypical teratoid rhabdoid …

A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models

…, KP Oza, KT Gallagher, R Kruger, MP Moyer… - Nature chemical …, 2015 - nature.com
Protein arginine methyltransferase-5 (PRMT5) is reported to have a role in diverse cellular
processes, including tumorigenesis, and its overexpression is observed in cell lines and …

Fusobacterium nucleatum increases proliferation of colorectal cancer cells and tumor development in mice by activating toll-like receptor 4 signaling to nuclear factor …

…, M Yin, C Pan, H Li, B Guo, Q Zhu, Q Wei, MP Moyer… - Gastroenterology, 2017 - Elsevier
Background & Aims Nearly 20% of the global cancer burden can be linked to infectious
agents. Fusobacterium nucleatum promotes tumor formation by epithelial cells via unclear …

Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma

…, M Porter-Scott, R Chesworth, MP Moyer… - Molecular cancer …, 2014 - AACR
Mutations within the catalytic domain of the histone methyltransferase EZH2 have been
identified in subsets of patients with non-Hodgkin lymphoma (NHL). These genetic alterations …

Effects of commercial anthocyanin-rich extracts on colonic cancer and nontumorigenic colonic cell growth

C Zhao, MM Giusti, M Malik, MP Moyer… - Journal of Agricultural …, 2004 - ACS Publications
Commercially prepared grape (Vitis vinifera), bilberry (Vaccinium myrtillus L.), and chokeberry
(Aronia meloncarpa E.) anthocyanin-rich extracts (AREs) were investigated for their …